Anavex Life Sciences (AVXL) Other Non Operating Income (2016 - 2025)
Anavex Life Sciences recorded quarterly Other Non Operating Income of $7000.0 in Q4 2025, up 40.0% quarter-over-quarter from $5000.0 in Q3 2025, and up 102.08% year-over-year from $3464.0 in Q4 2024.
Anavex Life Sciences' Other Non Operating Income history runs 10 years deep, the most recent figure standing at $7000.0 for Q4 2025.
- In Q4 2025, Other Non Operating Income rose 102.08% year-over-year to $7000.0; the TTM figure through Dec 2025 stood at $12000.0 (up 103.96% YoY), while the FY2025 annual figure was -$332000.0, down 275.66% from the prior year.
- Other Non Operating Income came in at $7000.0 for Q4 2025 at Anavex Life Sciences, up from $5000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $366000.0 in Q4 2022 to a low of -$732549.0 in Q2 2022.
- A 5-year average of -$82928.1 and a median of -$11000.0 in 2025 frame the typical range for Other Non Operating Income.
- On a YoY basis, Other Non Operating Income climbed as much as 561.09% in 2022 and fell as far as 355.34% in 2022.
- Anavex Life Sciences' Other Non Operating Income stood at $55363.0 in 2021, then jumped by 561.09% to $366000.0 in 2022, then tumbled by 57.38% to $156000.0 in 2023, then slumped by 316.03% to -$337000.0 in 2024, then jumped by 102.08% to $7000.0 in 2025.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $7000.0, $5000.0, and -$11000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Jun 30, 2025 | -11,000.00 |
| Mar 31, 2025 | 11,000.00 |
| Dec 31, 2024 | -337,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Jun 30, 2024 | 67,000.00 |
| Mar 31, 2024 | -150,000.00 |
| Dec 31, 2023 | 156,000.00 |
| Sep 30, 2023 | -186,000.00 |
| Mar 31, 2023 | -118,000.00 |
| Dec 31, 2022 | 366,000.00 |
| Sep 30, 2022 | -495,459.00 |
| Jun 30, 2022 | -732,549.00 |
| Mar 31, 2022 | 268,645.00 |
| Dec 31, 2021 | 55,363.00 |
| Sep 30, 2021 | -283,191.00 |
| Jun 30, 2021 | -160,880.00 |
| Mar 31, 2021 | -154,563.00 |
| Dec 31, 2020 | 332,634.00 |
| Sep 30, 2020 | 149,722.00 |
| Jun 30, 2020 | 248,665.00 |
| Mar 31, 2020 | -325,960.00 |
| Dec 31, 2019 | 53,113.00 |
| Sep 30, 2019 | -79,367.00 |
| Jun 30, 2019 | 36,978.00 |
| Mar 31, 2019 | 54,199.00 |
| Dec 31, 2018 | -4,507.00 |
| Sep 30, 2018 | -26,956.00 |
| Jun 30, 2018 | -16,475.00 |
| Mar 31, 2018 | -18,337.00 |
| Dec 31, 2017 | 11,979.00 |
| Sep 30, 2017 | -7,455.00 |
| Jun 30, 2017 | -65,932.00 |
| Mar 31, 2017 | 11,722.00 |
| Dec 31, 2016 | 14,082.00 |
| Sep 30, 2016 | -10,808.00 |
| Jun 30, 2016 | 8,924.00 |